1. Estimating the starting dose for entry into humans: principles and practice

   • Bruno G. Reigner
   • Karen Blesch

   Review Article 29 January 2002 Pages: 835 - 845

2. Inhibitory effects of H₁-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes

   • Nu He
   • Wen-Qi Zhang
   • Timi Edeki

   Pharmacokinetics and Disposition 17 January 2002 Pages: 847 - 851

3. Paracetamol disposition in renal allograft recipients

   • U. Martin
   • R. Temple
   • L. Prescott

   Pharmacokinetics and Disposition 19 January 2002 Pages: 853 - 856

4. N-acetyltransferase 2 polymorphism in sporadic Parkinson's disease in a Polish population

   • Monika Bialecka
   • Barbara Gawronska-Szklarz
   • Jan Stankiewicz

   Pharmacokinetics and Disposition 23 January 2002 Pages: 857 - 862

5. No clinically relevant drug interaction between paracetamol and phenprocoumon based on a pharmacoepidemiological cohort study in medical inpatients

   • Karin Fattinger
   • Roberto Frisullo
   • Malgorzata Roos

   Pharmacokinetics and Disposition 23 January 2002 Pages: 863 - 867

6. Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity

   • J. Persson
   • J. Hasselström
   • O. Almqvist

   Pharmacokinetics and Disposition 08 December 2001 Pages: 869 - 875

7. The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype

   • Ayman Al-Shurbaji
   • Juliette Säwe

   Pharmacokinetics and Disposition 29 January 2002 Pages: 877 - 881

8. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis

   • Serge Cremers
   • Rolf Sparidans
   • Socrates Papapoulos

   Pharmacokinetics and Disposition 29 January 2002 Pages: 883 - 890

9. Heavy metals in traditional Indian remedies

   • E. Ernst

   Pharmacoepidemiology and Prescription 08 December 2001 Pages: 891 - 896

10. Quality and impact of problem-oriented drug information: a method to change clinical practice among physicians?

    • Jan Schjøtt
    • Erik Pomp
    • Ane Gedde-Dahl

    Pharmacoepidemiology and Prescription 21 November 2001 Pages: 897 - 902

11. Descriptive study and pharmacotherapeutic intervention in patients with epilepsy or Parkinson's disease at nursing homes in southern Sweden

    • Patrik Midlöv
    • Åsa Bondesson
    • Peter Höglund

    Pharmacoepidemiology and Prescription 29 January 2002 Pages: 903 - 910

12. Forged medical prescriptions in a community pharmacy network in Midi-Pyrénées area: assessment of a falsification ratio

    • M. Llau
    • M. Lapeyre-Mestre
    • J. Montastruc

    Pharmacoepidemiology and Prescription 29 January 2002 Pages: 911 - 912

13. A double-blind comparison of the bronchodilatory effect of cumulative doses of salbutamol from Diskus (Accuhaler) and Turbuhaler

    • Per M. Gustafsson

    Letter to the Editors 01 February 2002 Pages: 913 - 914

14. Significant reduction of sertraline plasma levels by carbamazepine and phenytoin

    • Maria Pihlsgaård
    • Erik Eliasson

    Letter to the Editors 23 January 2002 Pages: 915 - 916

15. Heparin “hitts” again

    • Federico Goti
    • Wolfgang Korte
    • Marco Decurtins

    Letter to the Editors 29 January 2002 Pages: 917 - 918

16. Evaluation of isolated case reports on hepatotoxicity

    • Simona Gatti
    • Mario Bertazzoli

    Letter to the Editors 29 January 2002 Pages: 919 - 920

17. Letter to the editor by Drs. Gatti and Bertazzoli entitled “Evaluation of isolated case reports on hepatotoxicity”

    • Karin Fattinger
    • Gerd A. Kullak-Ublick

    Reply 29 January 2002 Pages: 921 - 922

18. Announcements

    Announcement 29 January 2002 Pages: 923 - 923